Track 06 of 9
Medication-Assisted Treatment
Implementation science, low-threshold access, stigma.
Medications for addiction treatment remain dramatically underutilized despite decades of evidence, with fewer than a quarter of patients with OUD receiving buprenorphine, methadone, or naltrexone. This track focuses on implementation science: emergency department buprenorphine initiation (the CA Bridge model), low-threshold telehealth prescribing protected by the post-COVID DEA flexibilities, jail and prison MOUD per the 2024 DOJ ADA guidance, and integration into primary care, OB, and HIV clinics. Sessions will address provider stigma, the elimination of the X-waiver under MAT Act, and pay-for-performance and bundled-payment models accelerating MAT scale-up.
Focus areas
- ED-initiated buprenorphine and the CA Bridge model
- Telehealth MOUD prescribing post-DEA flexibility extensions
- Carceral MOUD: DOJ ADA enforcement and jail induction protocols
- MAT Act implementation and post-X-waiver prescribing patterns
- Office-based opioid treatment in primary care, HIV, and OB clinics
- Provider stigma measurement and bias-reduction interventions
- Bundled payment and value-based contracting for SUD treatment